Skip to main content

Table 6 Mean change in PRO measures from week 24 to each follow-up visit

From: Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

PRO measure Time point from baseline of the ATLAS study
  Week 36 Week 52 Week 76 Week 104 Week 128 Week 156
BASDAI       
   n 278 274 270 262 242 236
   Mean change ± SD -0.2 ± 1.41 -0.4 ± 1.59 -0.5 ± 1.65 -0.6 ± 1.87 -0.6 ± 1.80 -0.5 ± 2.88
   P-valuea 0.004 < 0.001 < 0.001 < 0.001 < 0.001 0.009
BASFI       
   n 278 274 270 261 242 236
   Mean change ± SD -1.1 ± 10.68 -3.1 ± 13.07 -4.4 ± 14.22 -5.0 ± 15.90 -4.6 ± 15.87 -5.5 ± 14.27
   P-valuea 0.100 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
SF-36 PCS       
   n b 268 267 259 232 231
   Mean change ± SD b 1.8 ± 6.71 2.2 ± 7.35 2.4 ± 7.60 2.5 ± 8.54 2.6 ± 7.94
   P-valuea b < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
SF-36 MCS       
   n b 268 267 259 232 231
   Mean change ± SD b 0.7 (7.55) 0.1 (7.50) 0.6 (7.37) -1.2 (8.60) 0.2 (8.29)
   P-valuea b 0.150 0.892 0.176 0.033 0.718
ASQOL       
   n b 274 270 263 242 236
   Mean change ± SD b -0.5 (2.73) -0.7 (2.78) -1.0 (3.01) -0.8 (3.43) -1.0 (3.07)
   P-valuea b 0.002 < 0.001 < 0.001 < 0.001 < 0.001
  1. aP-values based on paired Student t-test.
  2. bMeasure not assessed at this time point.
  3. ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASDAI = Bath AS Disease Activity Index; BASFI = Bath AS Functional Index; MCS = Mental Component Summary; PCS = Physical Component Summary; PRO = patient-reported outcome; SF-36 = Short Form-36 Health Survey.